AbbVie obesity drug shows weight loss in early-stage trial

March 9, 2026 8:00 AM

AbbVie Inc. (NYSE: ABBV) reported that its experimental obesity treatment ABBV-295 demonstrated weight reduction of up to 9.79% in a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found